DEScover Registry: Drug-Eluting Stents vs Bare-Metal Stents
DEScover Registry: Drug-Eluting Stents vs Bare-Metal Stents
Drug-eluting stents (DES) have significantly reduced restenosis rates and the need for repeat revascularization procedures in patients who undergo percutaneous coronary intervention (PCI). Although there are plenty of data with regard to the safety and effectiveness of DES, few data are available about the selection and outcomes of bare-metal stents (BMS) and of the different types of DES (sirolimus-eluting stents [SES] and paclitaxel-eluting stents [PES]) in the United States.
The DEScover registry was initiated to characterize contemporary PCI in the United States, including patient selection, procedural strategies, and clinical outcomes, as well as to compare outcomes according to DES and with other PCI approaches. To date, the registry has collected data from more than 7700 patients treated at 140 participating sites in the United States.
Drug-eluting stents (DES) have significantly reduced restenosis rates and the need for repeat revascularization procedures in patients who undergo percutaneous coronary intervention (PCI). Although there are plenty of data with regard to the safety and effectiveness of DES, few data are available about the selection and outcomes of bare-metal stents (BMS) and of the different types of DES (sirolimus-eluting stents [SES] and paclitaxel-eluting stents [PES]) in the United States.
The DEScover registry was initiated to characterize contemporary PCI in the United States, including patient selection, procedural strategies, and clinical outcomes, as well as to compare outcomes according to DES and with other PCI approaches. To date, the registry has collected data from more than 7700 patients treated at 140 participating sites in the United States.
Source...